Barclays raised the firm’s price target on Tandem Diabetes to $55 from $39 and keeps an Overweight rating on the shares. The Q1 sales beat is a strong leading indicator for Mobi, which began a limited launch in the quarter, the analyst tells investors in a research note. The firm believes the company’s increased guidance could prove to be conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $50 from $35 at Piper Sandler
- Tandem Diabetes price target raised to $50 from $45 at Wells Fargo
- Tandem Diabetes price target raised to $45 from $35 at TD Cowen
- Tandem Diabetes price target raised to $36 from $28 at Baird
- Tandem Diabetes sees Fy24 revenue $868M, consensus $845.5M